Heterocyclic compound for inducing degradation of G12D mutant KRAS protein

• Main Authors: INAMURA, KOHEI, HAMAGUCHI, HISAO, MORIKAWA, TAKAHIRO, YOSHINARI, TOMOHIRO, WATANABE, HIDEYUKI, TAKAHASHI, FUMIE, NAGASHIMA, TAKEYUKI, KURAMOTO, KAZUYUKI, KAWAGUCHI, KENICHI, ISHIOKA, HIROKI, KAWAMINAMI, EIJI, IMAIZUMI, TOMOYOSHI
• Format: Patent
• Language: Chinese; English
• Published: 01.12.2023
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that heterocyclic compounds represented by the formula (I) and the formula (IA) have an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.